FDA Approves HYRNUO — Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. secured FDA approval for HYRNUO (sevabertinib), an oral anticancer agent indicated for advanced system mastocytosis, which is expected to expand the company’s portfolio in the hematology-oncology sector and bolster its market presence among patients requiring systemic therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed